Valuation: Acrux Limited

Market Cap 5.9M 4.15M 3.72M 3.44M 3.12M 5.83M 395M 41.17M 16.4M 207M 15.58M 15.25M 657M P/E 2025
-0.95x
P/E 2026 -8.4x
Enterprise Value 6.71M 4.72M 4.24M 3.92M 3.55M 6.63M 450M 46.85M 18.66M 235M 17.73M 17.35M 747M EV / Sales 2025
2.07x
EV / Sales 2026 1.08x
Free-Float
89.99%
Yield 2025 *
-
Yield 2026 -
1 week-9.09%
Current month+11.11%
1 month+5.26%
3 months-9.09%
6 months-9.09%
Current year-33.33%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.009
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.13
10 years 0.01
Extreme 0.009
0.35
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 24/08/2026
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-9.09%-28.57%-75.61% 4.15M
+0.50%+1.38%+57.09%+129.96% 1,148B
+0.86%+5.14%+45.00%+86.15% 652B
-0.14%+0.42%+25.69%+105.85% 505B
+0.34%+1.73%+52.74%+67.74% 384B
-0.63%-5.97%+61.93%+37.06% 348B
+1.52%+1.84%+30.70%+54.27% 294B
+0.83%+1.19%+2.89%+26.08% 264B
+0.87%+3.08%+54.69%+72.74% 244B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.43%+1.25%+33.72%+61.20% 403.72B
Weighted average by Cap. +0.47%+1.50%+44.52%+89.10%

Financials

2025 2026
Net sales 4.49M 3.16M 2.83M 2.62M 2.37M 4.43M 301M 31.33M 12.48M 157M 11.86M 11.61M 500M 6.58M 4.63M 4.16M 3.84M 3.48M 6.5M 441M 45.95M 18.3M 231M 17.39M 17.02M 733M
Net income -5.94M -4.19M -3.75M -3.47M -3.14M -5.87M -399M -41.51M -16.53M -209M -15.71M -15.37M -662M -604K -425K -381K -353K -319K -597K -40.5M -4.22M -1.68M -21.19M -1.6M -1.56M -67.27M
Net Debt 2.77M 1.95M 1.75M 1.62M 1.47M 2.74M 186M 19.35M 7.71M 97.25M 7.32M 7.17M 309M 813K 572K 513K 475K 430K 803K 54.51M 5.68M 2.26M 28.52M 2.15M 2.1M 90.55M
Projected Income Statement - Annual - Acrux Limited
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
29/10/26 A$0.0100 0.00% 30,000
28/10/26 A$0.0100 0.00% 464,443
27/10/26 A$0.0100 0.00% 2,729,548
26/10/26 A$0.0100 0.00% 7,120
23/10/26 A$0.0100 -9.09% 1,583,642

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Acrux Limited